Document Detail

Dry eye diagnosis and management in 2004.
MedLine Citation:
PMID:  15232468     Owner:  NLM     Status:  MEDLINE    
PURPOSE OF REVIEW: To document the changes in treatment paradigm for the management of dry eye. Restasis is 0.05% cyclosporine A and is the first immunomodulatory agent approved for treatment of dry eye. RECENT FINDINGS: Mounting evidence supports the inflammatory mechanism as explanation for the occurrence of dry eye disease. Immunomodulation has been shown to be effective in treating patients with moderate to severe dry eye disease caused by keratoconjunctivitis sicca. This addresses one of the two main forms of dry eye. There is a new report that immunomodulation using topical 0.05% cyclosporine A (Restasis) may also have a positive effect on meibomian gland dysfunction, the other main form of dry eye. SUMMARY: Dry eye disease is defined as an abnormality of tear film resulting in changes in the ocular surface. These changes may be seen on ocular examination with the use of fluorescein and supravital staining techniques. Classification of dry eye disease shows two main types: aqueous deficiency and evaporative loss. There is hope that both of these types of dry eye will respond to immunomodulation therapy. Restasis shows promise as the first of these agents to be approved as therapy to treat moderate to severe dry eye disease.
Henry D Perry; Eric D Donnenfeld
Related Documents :
22983638 - Igg4-related disease involving the sclera.
23885268 - Subjective poor sleep quality in chinese patients with parkinson's disease without deme...
10218308 - Hplc analysis of closed, open, and reflex eye tear proteins.
15952728 - Diagnostic potential of tear proteomic patterns in sjögren's syndrome.
12667648 - Interleukin-6 alters sleep of rats.
18241238 - A graph-theory framework for evaluating landscape connectivity and conservation planning.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in ophthalmology     Volume:  15     ISSN:  1040-8738     ISO Abbreviation:  Curr Opin Ophthalmol     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-07-02     Completed Date:  2004-11-09     Revised Date:  2006-10-13    
Medline Journal Info:
Nlm Unique ID:  9011108     Medline TA:  Curr Opin Ophthalmol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  299-304     Citation Subset:  IM    
Department of Ophthalmology, Weill-Cornell School of Medicine, and Research Laboratories, New York Eye and Ear Infirmary, New York, New York 11570, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dry Eye Syndromes / classification,  diagnosis*,  etiology,  therapy*
Ophthalmology / trends

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Review of immunosuppressive drug therapy in uveitis.
Next Document:  Advances in the use of adhesives in ophthalmology.